Byondis
Panagiota Spantidea currently serves as a senior scientist in immuno-oncology at Byondis, focusing on in vivo pharmacology, toxicology, and DMPK since February 2022. Prior experience includes a role as a postdoctoral researcher in experimental hematology at Vall d´Hebron Institute of Oncology from December 2020 to January 2022, and postdoctoral positions at Erasmus MC, where Spantidea contributed to projects related to urinary bladder emptying disorders and cancer immunology. Academic qualifications include a PhD from the University of Patras with a focus on T helper lymphocyte plasticity, a Master's degree in immunology, and a Bachelor's degree in biology with a specialization in immunology.
This person is not in any teams
Byondis
1 followers
With a passion for outsmarting relentless cancers and autoimmune diseases, Byondis takes precision medicines to the next level. We are driven by one goal: providing novel treatments with high efficacy and low systemic toxicity for patients with high unmet medical needs. Many companies work in the areas of unmet need. What differentiates Byondis is its focus on producing a broad spectrum of molecular concepts, ranging from small molecule chemistries to complex protein structures. We engineer smaller and larger molecular functionalities that may be combined to target the right part of the body. This involves: • Next generation antibody-drug conjugates (ADCs), including proprietary linker-drug (LD) technology to generate multiple ADC candidates targeting different indications • Site-specific conjugation technology • Monoclonal antibodies (mAbs) • Highly selective, disease-targeting small molecules The success of our company fully depends on our people. To them, we aim to provide a fair, open and inspiring working environment, where there is room for ambition, entrepreneurship and new initiatives leading to new medicines that save and transform patients’ lives.